← Ticker index
REGN
Ticker
REGN
Regeneron Pharmaceuticals Inc.
Healthcare
Congressional Trades
98
by 11 members
Ticker disclosure brief
Congressional disclosure records for REGN
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
BUY · 2026-06-16
Largest range
$15K – $50K
Jefferson Shreve
Longest observed gap
147d
Tommy Tuberville
Highest 30d vs SPY
26.0%
Ro Khanna
Purchase rows
33
34%
Sale rows
61
62%
Disclosed midpoint
$931K
range estimate
Unique Traders
11
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats76 · 78%
Republicans22 · 22%
Lobbying filings
all →- 2026-07-15$90KREGENERON PHARMACEUTICALS INC.There is no current bill filed. Engagement with HHS regarding issues related to healthcare.
- 2026-07-08$30KREGENERON PHARMACEUTICALS INC.Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations, agreements, implementation, and reporting related to the taxation of global income. Issues related to IRC sections 11, 951A, and 250.
- 2026-05-04$50KREGENERON PHARMACEUTICALS INC.Biodefense and Medicare prescription drug funding
- 2026-04-20$640KREGENERON PHARMACEUTICALS INCPrivacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program. Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers. Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers. Trade and tariff issues related to corporations. Tax and inflation issues related to corporations.
- 2026-04-20$90KREGENERON PHARMACEUTICALS INC.Provide strategic counsel and advocate on issues related to matters of importance to domestic pharmaceutical manufacturers
- 2026-04-20$0REGENERON PHARMACEUTICALS INC.Outreach related to FY 2027 appropriations. Outreach related to FY 2027 appropriations.
- 2026-04-15$90KREGENERON PHARMACEUTICALS INC.There is no current bill filed. Engagement with HHS regarding issues related to healthcare.
- 2026-04-01$30KREGENERON PHARMACEUTICALS INC.Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, and 174.
- 2026-01-21$50KREGENERON PHARMACEUTICALS INC.Biodefense funding
- 2026-01-20$610KREGENERON PHARMACEUTICALS INCTax and inflation issues related to corporations. Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program. Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers. Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers. Trade and tariff issues related to corporations.
Loading trade analytics…
All Disclosed Trades
Page 3 · 25 of 98 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2025-04-10 | RByron Donalds | SELL | $1K – $15K | 25d | receipt → |
| 2025-02-25 | RRobert Bresnahan | SELL | $1K – $15K | 30d | receipt → |
| 2025-02-25 | RRobert Bresnahan | SELL | $1K – $15K | 30d | receipt → |
| 2025-02-12 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-02-12 | DJulie Johnson | SELL | $1K – $15K | 28d | receipt → |
| 2025-02-19 | DRo Khanna | SELL | $1K – $15K | 15d | receipt → |
| 2025-02-25 | DRo Khanna | SELL | $1K – $15K | 9d | receipt → |
| 2025-02-25 | DRo Khanna | SELL | $1K – $15K | 9d | receipt → |
| 2025-01-15 | DJulie Johnson | BUY | $1K – $15K | 28d | receipt → |
| 2025-01-15 | DJulie Johnson | BUY | $1K – $15K | 28d | receipt → |
| 2025-01-24 | DJosh Gottheimer | SELL | $1K – $15K | 17d | receipt → |
| 2025-01-24 | DJosh Gottheimer | SELL | $1K – $15K | 17d | receipt → |
| 2025-01-17 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2025-01-17 | DRo Khanna | BUY | $1K – $15K | 20d | receipt → |
| 2024-11-01 | DJonathan Jackson | SELL | $1K – $15K | 41d | receipt → |
| 2024-11-13 | DJonathan Jackson | SELL | $15K – $50K | 29d | receipt → |
| 2024-11-01 | DJonathan Jackson | SELL | $1K – $15K | 41d | receipt → |
| 2024-11-13 | DJonathan Jackson | SELL | $15K – $50K | 29d | receipt → |
| 2024-11-12 | DRo Khanna | SELL | $1K – $15K | 23d | receipt → |
| 2024-11-12 | DRo Khanna | SELL | $1K – $15K | 23d | receipt → |
| 2024-11-29 | DJosh Gottheimer | SELL | $1K – $15K | 6d | receipt → |
| 2024-11-19 | DJosh Gottheimer | SELL | $1K – $15K | 16d | receipt → |
| 2024-11-19 | DJosh Gottheimer | SELL | $1K – $15K | 16d | receipt → |
| 2024-11-29 | DJosh Gottheimer | SELL | $1K – $15K | 6d | receipt → |
| 2024-11-13 | DJonathan Jackson | SELL | $15K – $50K | 20d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.